Direct-to-angio approach from loCal hOspitals based on a PoInt-of-care bLOod Test for LVO (COPILOT) is a multi-center, prospective, cluster-randomized crossover trial that will evaluate if the triage assessment to thrombectomy puncture time is shorter after performing the LVOne testing compared to current management standards in patients with suspected large vessel occlusion.
The COPILOT trial utilizes a cluster randomized crossover design within the Sistema de Salud Menonita (SSM) hospital network to evaluate if early detection of large vessel occlusion (LVO) stroke with a novel blood test can accelerate the time from triage assessment to thrombectomy puncture. It will unfold in three phases: Phase 0 - Baseline Data Collection (3 months): Before the random allocation, all clusters undergo data collection on baseline characteristics and outcome measures to confirm/set a pre-intervention comparison ground. Phase 0 patients will receive the current standard of care. An interim analysis will check recruitment rates and explore the need for additional clusters for adequate study power. Phase 1 - Intervention and Control (12 months): Clusters are randomized to either the intervention or control group, with the intervention arm implementing the LVOne test and the control arm continuing standard care without the LVOne test. Data analysts remain blinded to group allocation, while an interim analysis revisits recruitment and primary outcomes to assess whether additional clusters are required. Phase 2 - Crossover (12 months): Clusters switch roles from Phase 1, allowing every cluster to experience both the intervention and control conditions, facilitating within-cluster comparisons. The nature of the intervention prevents the blinding of participants and staff.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Enrollment
520
Participants will receive the diagnostic standard of care: standard laboratory workup, non-contrast brain CT, brain CTA, brain CTP, or brain MRI.
Participants will receive the LVOne test, which will measure D-dimer and Glial Fibrillary Acidic Protein (GFAP) levels to diagnose acute stroke.
Hospital Menonita Caguas
Caguas, PR, Puerto Rico
Change in the time from triage assessment to thrombectomy puncture
The difference in time from the participant triage assessment to thrombectomy puncture.
Time frame: 24 hours
Time from spoke hospital triage assessment to LVOne test in intervention
Difference in time from triage assessment to the performance of the LVOne test in the intervention group.
Time frame: 24 hours
Time from HUB hospital triage assessment to LVOne test in intervention
The difference in time from the HUB hospital triage assessment to the performance of the LVOne test.
Time frame: 24 hours
Time from HUB hospital triage assessment to thrombectomy puncture
The difference in time from the HUB hospital triage assessment to the thrombectomy puncture.
Time frame: 24 hours
Thrombectomy rate (proportion of treated LVO)
The number of participants that received thrombectomy.
Time frame: 24 hours
Length of hospital stay
The participant's hospitalization period.
Time frame: From date of randomization until the date of discharge or date of death from any cause while patient is in hospital, whichever came first, assessed up to 30 days
Length of ICU stay
The participant's hospitalization period in the intensive care unit (ICU).
Time frame: From date of randomization until the date of discharge or date of death from any cause while patient is in hospital, whichever came first, assessed up to 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Diagnostic accuracy for LVO detection
The ability of the test to correctly identify large vessel occlusion (LVO) in patients with suspected acute ischemic stroke. Diagnostic accuracy will be assessed by comparing the test results to the reference imaging standards.
Time frame: At the time of initial assessment and confirmed by diagnostic imaging within 24 hours
Diagnostic accuracy for intracerebral hemorrhage detection
The ability of the LVOne test to correctly detect intracerebral hemorrhage (ICH) in patients presenting with acute stroke symptoms. Diagnostic accuracy will be determined by comparing LVOne test results to diagnostic imaging.
Time frame: At the time of initial assessment and confirmed by diagnostic imaging within 24 hours
Modified Rankin Scale (mRS)
The modified Rankin Scale (mRS) is a measure of functional outcome assessing the degree of disability or dependence in daily activities. The scale ranges from 0 (no symptoms) to 6 (death).
Time frame: At the time of initial assessment, 24 hours, at discharge, 3 months, 6 months, and 12 months